Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.71
(2.91%)
USD 0.71
(2.91%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 176.23 Million USD | 58.34% |
| 2022 | 111.29 Million USD | 0.54% |
| 2021 | 110.7 Million USD | -6.34% |
| 2020 | 118.19 Million USD | 15.39% |
| 2019 | 102.42 Million USD | 21.29% |
| 2018 | 84.45 Million USD | 130.95% |
| 2017 | 36.56 Million USD | 88.6% |
| 2016 | 19.38 Million USD | -50.96% |
| 2015 | 39.53 Million USD | -13.8% |
| 2014 | 45.87 Million USD | 90.07% |
| 2013 | 24.13 Million USD | 11.44% |
| 2012 | 21.65 Million USD | 109.86% |
| 2011 | 10.31 Million USD | -50.4% |
| 2010 | 20.8 Million USD | -6.23% |
| 2009 | 22.18 Million USD | 37.08% |
| 2008 | 16.18 Million USD | 77.91% |
| 2007 | 9.09 Million USD | 15.38% |
| 2006 | 7.88 Million USD | 217.43% |
| 2005 | 2.48 Million USD | 88.9% |
| 2004 | 1.31 Million USD | -49.01% |
| 2003 | 2.57 Million USD | -40.62% |
| 2002 | 4.34 Million USD | -11.1% |
| 2001 | 4.88 Million USD | 42.3% |
| 2000 | 3.43 Million USD | 56.05% |
| 1999 | 2.2 Million USD | 7.95% |
| 1998 | 2.03 Million USD | 76.91% |
| 1997 | 1.15 Million USD | 82.28% |
| 1996 | 632 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 356 Thousand USD | -25.99% |
| 2024 Q1 | 481 Thousand USD | -76.44% |
| 2023 FY | 176.23 Million USD | 58.34% |
| 2023 Q2 | 6.83 Million USD | -95.67% |
| 2023 Q3 | 9.39 Million USD | 37.5% |
| 2023 Q4 | 2.04 Million USD | -78.27% |
| 2023 Q1 | 157.95 Million USD | 480.08% |
| 2022 Q3 | 26.46 Million USD | -9.93% |
| 2022 FY | 111.29 Million USD | 0.54% |
| 2022 Q1 | 28.23 Million USD | 0.88% |
| 2022 Q2 | 29.37 Million USD | 4.06% |
| 2022 Q4 | 27.23 Million USD | 2.91% |
| 2021 Q2 | 27.87 Million USD | 6.06% |
| 2021 Q1 | 26.28 Million USD | 1.86% |
| 2021 Q4 | 27.98 Million USD | -2.02% |
| 2021 Q3 | 28.56 Million USD | 2.48% |
| 2021 FY | 110.7 Million USD | -6.34% |
| 2020 Q2 | 21.55 Million USD | 64.83% |
| 2020 Q1 | 13.07 Million USD | -76.16% |
| 2020 Q4 | 25.8 Million USD | -55.33% |
| 2020 Q3 | 57.76 Million USD | 168.0% |
| 2020 FY | 118.19 Million USD | 15.39% |
| 2019 Q2 | 17.54 Million USD | 117.42% |
| 2019 Q4 | 54.85 Million USD | 149.8% |
| 2019 Q3 | 21.95 Million USD | 25.13% |
| 2019 FY | 102.42 Million USD | 21.29% |
| 2019 Q1 | 8.07 Million USD | -69.93% |
| 2018 Q2 | 21.41 Million USD | 69.47% |
| 2018 Q4 | 26.83 Million USD | 13.9% |
| 2018 FY | 84.45 Million USD | 130.95% |
| 2018 Q1 | 12.63 Million USD | -3.36% |
| 2018 Q3 | 23.56 Million USD | 10.02% |
| 2017 Q1 | 3.42 Million USD | -61.61% |
| 2017 Q2 | 8.25 Million USD | 140.96% |
| 2017 Q3 | 11.81 Million USD | 43.12% |
| 2017 Q4 | 13.07 Million USD | 10.71% |
| 2017 FY | 36.56 Million USD | 88.6% |
| 2016 Q3 | 2.82 Million USD | -23.74% |
| 2016 Q1 | 3.94 Million USD | -56.78% |
| 2016 FY | 19.38 Million USD | -50.96% |
| 2016 Q2 | 3.7 Million USD | -6.09% |
| 2016 Q4 | 8.92 Million USD | 216.05% |
| 2015 Q1 | 13.49 Million USD | -9.77% |
| 2015 Q2 | 8.35 Million USD | -38.05% |
| 2015 FY | 39.53 Million USD | -13.8% |
| 2015 Q3 | 8.56 Million USD | 2.52% |
| 2015 Q4 | 9.12 Million USD | 6.44% |
| 2014 Q2 | 10.38 Million USD | 27.96% |
| 2014 FY | 45.87 Million USD | 90.07% |
| 2014 Q3 | 12.41 Million USD | 19.57% |
| 2014 Q4 | 14.95 Million USD | 20.42% |
| 2014 Q1 | 8.11 Million USD | 18.15% |
| 2013 Q1 | 4.62 Million USD | -48.24% |
| 2013 Q3 | 5.7 Million USD | -17.7% |
| 2013 Q4 | 6.86 Million USD | 20.36% |
| 2013 FY | 24.13 Million USD | 11.44% |
| 2013 Q2 | 6.93 Million USD | 49.99% |
| 2012 Q1 | 3.24 Million USD | -31.72% |
| 2012 Q2 | 4.57 Million USD | 41.09% |
| 2012 Q3 | 4.9 Million USD | 7.28% |
| 2012 Q4 | 8.93 Million USD | 82.01% |
| 2012 FY | 21.65 Million USD | 109.86% |
| 2011 Q1 | 2.2 Million USD | -53.08% |
| 2011 Q2 | 1.51 Million USD | -31.18% |
| 2011 Q3 | 1.85 Million USD | 22.66% |
| 2011 Q4 | 4.74 Million USD | 155.68% |
| 2011 FY | 10.31 Million USD | -50.4% |
| 2010 Q4 | 4.68 Million USD | 59.33% |
| 2010 Q1 | 6.64 Million USD | -35.08% |
| 2010 FY | 20.8 Million USD | -6.23% |
| 2010 Q2 | 6.52 Million USD | -1.85% |
| 2010 Q3 | 2.94 Million USD | -54.9% |
| 2009 Q4 | 10.24 Million USD | 152.06% |
| 2009 Q2 | 4.72 Million USD | 49.7% |
| 2009 Q1 | 3.15 Million USD | -53.8% |
| 2009 Q3 | 4.06 Million USD | -14.03% |
| 2009 FY | 22.18 Million USD | 37.08% |
| 2008 Q2 | 2.84 Million USD | 2.78% |
| 2008 FY | 16.18 Million USD | 77.91% |
| 2008 Q4 | 6.83 Million USD | 82.48% |
| 2008 Q3 | 3.74 Million USD | 31.77% |
| 2008 Q1 | 2.76 Million USD | -0.07% |
| 2007 Q3 | 2.32 Million USD | -10.02% |
| 2007 Q2 | 2.58 Million USD | 81.72% |
| 2007 Q1 | 1.42 Million USD | -35.16% |
| 2007 Q4 | 2.76 Million USD | 19.01% |
| 2007 FY | 9.09 Million USD | 15.38% |
| 2006 FY | 7.88 Million USD | 217.43% |
| 2006 Q3 | 1.77 Million USD | 0.11% |
| 2006 Q2 | 1.77 Million USD | -16.81% |
| 2006 Q1 | 2.13 Million USD | 52.9% |
| 2006 Q4 | 2.19 Million USD | 23.27% |
| 2005 Q3 | 412 Thousand USD | -1.44% |
| 2005 Q2 | 418 Thousand USD | 63.28% |
| 2005 Q1 | 256 Thousand USD | 28.0% |
| 2005 FY | 2.48 Million USD | 88.9% |
| 2005 Q4 | 1.39 Million USD | 239.08% |
| 2004 FY | 1.31 Million USD | -49.01% |
| 2004 Q1 | 811 Thousand USD | -19.14% |
| 2004 Q2 | 132 Thousand USD | -83.72% |
| 2004 Q3 | 172 Thousand USD | 30.3% |
| 2004 Q4 | 200 Thousand USD | 16.28% |
| 2003 FY | 2.57 Million USD | -40.62% |
| 2003 Q1 | 551 Thousand USD | -77.64% |
| 2003 Q4 | 1 Million USD | 97.83% |
| 2003 Q3 | 507 Thousand USD | -2.12% |
| 2003 Q2 | 518 Thousand USD | -5.99% |
| 2002 Q4 | 2.46 Million USD | 143.48% |
| 2002 FY | 4.34 Million USD | -11.1% |
| 2002 Q3 | 1.01 Million USD | 176.5% |
| 2002 Q2 | 366 Thousand USD | -26.95% |
| 2002 Q1 | 501 Thousand USD | -76.85% |
| 2001 Q1 | 634 Thousand USD | -39.96% |
| 2001 FY | 4.88 Million USD | 42.3% |
| 2001 Q4 | 2.16 Million USD | 192.83% |
| 2001 Q3 | 739 Thousand USD | -45.18% |
| 2001 Q2 | 1.34 Million USD | 112.62% |
| 2000 Q2 | 747 Thousand USD | -7.43% |
| 2000 Q1 | 807 Thousand USD | 0.0% |
| 2000 FY | 3.43 Million USD | 56.05% |
| 2000 Q4 | 1.05 Million USD | 28.31% |
| 2000 Q3 | 823 Thousand USD | 10.17% |
| 1999 FY | 2.2 Million USD | 7.95% |
| 1998 FY | 2.03 Million USD | 76.91% |
| 1997 FY | 1.15 Million USD | 82.28% |
| 1996 FY | 632 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -1012.365% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -4935.2% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -463.96% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 97.421% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -557.018% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 90.361% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 55.871% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -1955.663% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 34.874% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 92.715% |
| bluebird bio, Inc. | 29.49 Million USD | -497.457% |
| Blueprint Medicines Corporation | 249.38 Million USD | 29.332% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -740.481% |
| Imunon, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 63.466% |
| Dynavax Technologies Corporation | 232.28 Million USD | 24.131% |
| Editas Medicine, Inc. | 78.12 Million USD | -125.583% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 83.205% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -51.488% |
| Exelixis, Inc. | 1.83 Billion USD | 90.371% |
| FibroGen, Inc. | 147.75 Million USD | -19.276% |
| Geron Corporation | 237 Thousand USD | -74259.494% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 78.748% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -38.717% |
| Illumina, Inc. | 4.5 Billion USD | 96.087% |
| Incyte Corporation | 3.69 Billion USD | 95.231% |
| Insmed Incorporated | 305.2 Million USD | 42.258% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -385.822% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 77.626% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -14721.867% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 98.824% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 95.348% |
| Evolus, Inc. | 202.08 Million USD | 12.793% |
| Myriad Genetics, Inc. | 678.4 Million USD | 74.022% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 90.661% |
| OPKO Health, Inc. | 863.49 Million USD | 79.591% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 85.826% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 70.992% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.881% |
| Waters Corporation | 2.95 Billion USD | 94.039% |
| Zoetis Inc. | 8.54 Billion USD | 97.937% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 98.214% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.589% |
| Biogen Inc. | 9.83 Billion USD | 98.208% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 98.656% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 2749.707% |
| Nektar Therapeutics | 90.12 Million USD | -95.548% |
| TG Therapeutics, Inc. | 233.66 Million USD | 24.578% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 96.215% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |